Rivastigmine
- Generic Name
- Rivastigmine
- Brand Names
- Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O2
- CAS Number
- 123441-03-2
- Unique Ingredient Identifier
- PKI06M3IW0
- Background
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
- Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
- Associated Conditions
- Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Japan Approves Luye Pharma's Twice-Weekly Rivastigmine Patch for Alzheimer's Disease
• Japan's Ministry of Health, Labour and Welfare has approved Luye Pharma's innovative Rivastigmine Twice Weekly Transdermal Patch (Rivaluen® LA Patch) for mild to moderate Alzheimer's disease, marking the first extended-release rivastigmine transdermal formulation in the country.
• The novel delivery system requires application only twice weekly versus traditional daily patches, potentially improving medication adherence in a patient population that often struggles with medication management as an early symptom of the disease.
• Towa Pharmaceutical will commercialize the product in Japan under a 2020 licensing agreement, while the patch has already received approval in multiple European countries and China, with expansion planned for Southeast Asia and Latin America.
Cholinesterase Inhibitors Show Promise in Managing Cognitive Decline in Lewy Body Dementia
• A recent 10-year study suggests that cholinesterase inhibitors (ChEIs) may be effective in managing cognitive decline in patients with Lewy body dementia (LBD).
• Donepezil and galantamine, types of ChEIs, demonstrated the most promise in reducing cognitive decline over a five-year period in LBD patients.
• Rivastigmine showed a significant beneficial effect in reducing mortality risk after a one-year follow-up, highlighting its potential in managing LBD.
• The study indicates that higher doses of ChEIs may provide greater cognitive benefits, while memantine showed no significant cognitive effect in LBD patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath